OBJECTIVES:  In the context of gradual implementation of economic evaluation of medicines, the Catalan Health Service (CatSalut) aimed to review decisions made and cost-effectiveness criteria considered by seven Health Technology Assessment (HTA) agencies for a sample of 49 oncologic indications. METHODS:  Included agencies were HAS (France), IQWIG (Germany), NICE (United Kingdom), PBAC (Australia), pCODR (Canada), SMC (Scotland) and TLV (Sweden). Reports available online on agencies’ websites covering the target indications until October 2015 were reviewed in order to extract information on decisions made and criteria considered. For those reports including an EE, relationship between the type of recommendation and the estimated incremental cost-effectiveness ratio (ICER) was assessed. RESULTS:  Overall,